Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

11 Sept 2019

Abstract excerpt

The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains nonresponsive, raising the need of how to identify anlotinib-responsive patients. In the present study, we aimed to screen potential biomarkers for anlotinib-responsive stratification via integrated transcriptome analysis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31572680
DOI: 10.3389/fonc.2019.00886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd LinePMID 31572680Read ↗

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cellsSemantic proximity Read ↗

Integrated machine learning survival framework for consensus modeling in a large multicenter cohort of NSCLC resistant to aumolertinibSemantic proximity Read ↗

Screening anlotinib responders via blood-based proteomics in non-small cell lung cancerSemantic proximity Read ↗

Integrated machine learning survival framework for consensus modeling in a large multicenter cohort of NSCLC resistant to aumolertinib.Semantic proximity Read ↗

Serum Proteomic Profile of Advanced NSCLC and Exploration of Efficacy Markers for Anti-Angiogenic DrugsSemantic proximity Read ↗

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.Semantic proximity Read ↗

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.